Pacific Biosciences Of California (PACB) Change in Receivables (2010 - 2026)

Pacific Biosciences Of California has reported Change in Receivables for 17 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Change in Receivables rose 186.6% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was -$1.2 million, a 555.11% decrease from a year earlier, with the FY2025 full-year figure at $7.9 million, up 187.16% from the prior year.
• Change in Receivables was $1.8 million for Q2 2026 at Pacific Biosciences Of California, up from -$6.1 million in the prior quarter.
• The five-year high for Change in Receivables was $10.8 million in Q1 2023, with the low at -$6.3 million in Q1 2024.
• Average Change in Receivables over 5 years is $381277.8, with a median of -$91000.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Change in Receivables slumped 1445.76% in 2022, then soared 359.92% in 2025.
• Over 5 years, Change in Receivables stood at -$4.0 million in 2022, then soared by 254.38% to $6.1 million in 2023, then plunged by 130.33% to -$1.9 million in 2024, then surged by 359.92% to $4.8 million in 2025, then slumped by 63.7% to $1.8 million in 2026.
• The last three Change in Receivables figures came in at $1.8 million (Q2 2026), -$6.1 million (Q1 2026), and $4.8 million (Q4 2025), per Business Quant data.